Skip to main content
OpenTrials

Clinical trial condition

Secondary Hypogonadism

Explore clinical trials studying Secondary Hypogonadism. Study availability and eligibility vary by location and protocol.

19 public trials 0 recruiting studies
Refine in advanced search Browse all conditions

Secondary Hypogonadism trial results

Completed

Phase III Study to Evaluate Morning Testosterone Normalization in Overweight Men With Secondary Hypogonadism

NCT01739595

Conditions
Endocrine System Diseases, Gonadal Disorders, Hypogonadism, +1 more
Locations
  • Coastal Clinical Research Mobile, Alabama, United States
  • Baptist Health Center for Clinical Research Little Rock, Arkansas, United States
  • Rancho Cucamonga Clinical Trials Rancho Cucamonga, California, United States
  • Meridien Research Bradenton, Florida, United States
View all 13 locations
View Trial Details
Completed

Phase III Study to Evaluated Morning Testosterone Normalization in Men With Secondary Hypogonadism

NCT01532414

Conditions
Endocrine System Diseases, Gonadal Disorders, Hypogonadism, +1 more
Locations
  • Coastal Clinical Research Mobile, Alabama, United States
  • Baptist Health Center for Clinical Research Little Rock, Arkansas, United States
  • SC Clinical Research Garden Grove, California, United States
  • Mission Internal Medicine Group Mission Viejo, California, United States
View all 23 locations
View Trial Details
Completed

A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%

NCT01993225

Conditions
Endocrine System Diseases, Gonadal Disorders, Hypogonadism, +1 more
Locations
  • Birmingham, Alabama, United States
  • Mobile, Alabama, United States
  • Evanston, Illinois, United States
  • Lexington, Kentucky, United States
View Trial Details
Completed

A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%

NCT01993212

Conditions
Endocrine System Diseases, Gonadal Disorders, Hypogonadism, +1 more
Locations
  • Jacksonville, Florida, United States
  • Albany, New York, United States
  • Raleigh, North Carolina, United States
  • Cleveland, Ohio, United States
View Trial Details

Related conditions